Indivior launches $175M accelerated share buyback

Indivior Pharmaceuticals has initiated a $175M accelerated share repurchase agreement with Barclays, part of its $400M share repurchase program. An upfront payment will be made to Barclays, with an initial delivery of 3,717,473 shares expected shortly after execution. Final settlement is anticipated by June 2026, and the ASR is not expected to affect Indivior's financial guidance. The remaining $100M of the repurchase authorization may be utilized for further repurchases depending on market conditions.

Indivior Pharmaceuticals (INDV) has entered into a $175M accelerated share repurchase agreement with Barclays (BCS). The ASR will be executed under Indivior’s existing $400M share repurchase program. Under the ASR agreement, Indivior (INDV) will make an upfront payment of $175M to Barclays and expects to receive an initial delivery of 3,717,473 sha...